Tag Archives: Cipla

India runs out of life-saving HIV drug for children

Posted on March 6, 2017 by donttradeourlivesaway

By Vidya Krishnan, The Hindu | March 6, 2017 Cipla, sole manufacturer of Lopinavir syrup, stopped production of the drug after govt. failed to clear dues Desperate over withdrawal of a life saving drug, children living with HIV (CLHIV) have … Continue reading →

Posted in HIV/Aids, Stockouts, Uncategorized | Tagged , | Leave a comment

Requesting PM Modi to help children get HIV medicines

Posted on March 3, 2017 by donttradeourlivesaway

Dear Prime Minister Modi, Minister Jaitley and Minister Nadda, Developing a proactive approach to the prevention of HIV medicines shortages Shortages of medicines have been a global problem for the past decade and have also increasingly affected the National AIDS Control … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment

New development in the COPD drug Indaceterol

Posted on November 20, 2014 by donttradeourlivesaway

The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at … Continue reading →

Posted in Pricing | Tagged , , | Leave a comment

Cipla asks government to revoke five patents held by Novartis

Posted on October 30, 2014 by donttradeourlivesaway

Source: Economic Times 30 Oct 2014 NEW DELHI: Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug Onbrez and launched its generic version of indacaterol at a fifth of … Continue reading →

Posted in Generics, IP Rights, Patent Opposition, Patents | Tagged , , | Leave a comment

Ranbaxy drugs are safe: South African regulator

Posted on June 6, 2013 by donttradeourlivesaway

Source: The Hindu June5,2013 Generic drugs distributed in South Africa by Ranbaxy Laboratories are ‘safe’ and ‘efficacious’, the country’s regulator body said on Wednesday, days after the beleaguered drug maker paid a fine of $500 million in the U.S. for … Continue reading →

Posted in Generics, WHO | Tagged , , , , , , , | Leave a comment

Lobby fears norms violation in Cipla’s biosimilar drug

Posted on May 15, 2013 by donttradeourlivesaway

Source: The Economic Times May 14,2013 MUMBAI: A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla’s first biosimilar drug Etanercept, used for the treatment ofrheumatic disorders. The Association of Biotechlogy Led Enterprises (ABLE) fears … Continue reading →

Posted in Biologics/Biosimilars | Tagged , , , , | Leave a comment

Cipla gets relief in patent battle with Pfizer

Posted on February 12, 2013 by donttradeourlivesaway

Source: Business Standard by Sushmi Dey  February 12,2013 In what could mean a major setback for Pfizer, the patent office has again ruled in favour of Cipla, reinstating its earlier decision to revoke the American company’s patent for cancer drug … Continue reading →

Posted in Patents | Tagged , , , | Leave a comment

Testing the mettle of drug-makers

Posted on December 31, 2012 by donttradeourlivesaway

December 25, 2012 Hindu Business Line If there is a single defining factor in the last 12 months in the pharmaceutical industry, it has to be the attention coming back, even if just a bit, to public health. This is … Continue reading →

Posted in Compulsory Licensing, FDI, Novartis Case, Pricing, Uncategorized | Tagged , , , , | Leave a comment

Merck’s frivolous patent on asthma inhaler revoked

Posted on December 12, 2012 by donttradeourlivesaway

On 10 December, Schering Corporation’s (now Merck) patent on an asthma inhaler has been revoked. In 2004, Schering Corporation filed an application (402/CHENP/2004) in India claiming a product patent on an aerosol suspension formulation containing two active drugs mometasone furoate and formoterol fumarate. These drugs … Continue reading →

Posted in Indian Patent Law, Patent Opposition, Post-grant opposition | Tagged , , | Leave a comment

Cipla’s brave act: Will cancer treatment go the AIDS way?

Posted on November 14, 2012 by donttradeourlivesaway

In March, when Indian drug company Cipla cut by three-fourth, the prices of certain cancer medicines, we called it a game-changer that was similar to the AIDS-treatment breakthrough the company had achieved a decade ago. Although Cipla’s initiative appeared to … Continue reading →

Posted in Compulsory Licensing | Tagged , , | Leave a comment